Get the Stockscreener App
3.94
1.50%
-0.06
Aileron Therapeutics Inc stock is traded at $3.94, with a volume of 23,290.
It is down -1.50% in the last 24 hours and up +10.99% over the past month.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
See More
Previous Close:
$4.00
Open:
$4.05
24h Volume:
23,290
Relative Volume:
0.31
Market Cap:
$83.41M
Revenue:
-
Net Income/Loss:
$-12.94M
P/E Ratio:
-1.3873
EPS:
-2.84
Net Cash Flow:
$-13.83M
1W Performance:
-3.43%
1M Performance:
+10.99%
6M Performance:
+4.79%
1Y Performance:
+239.66%
1-Day Range:
$3.83
$4.075
1-Week Range:
$3.46
$4.16
52-Week Range:
$1.19
$7.42
Aileron Therapeutics Inc Stock (ALRN) Company Profile
Name
Aileron Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN, MA
Aileron Therapeutics Inc Stock (ALRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Aileron Therapeutics Inc Stock (ALRN) Latest News
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - StockTitan
Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Drops By 14.2% - MarketBeat
Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Increases By 15.8% - MarketBeat
ALRNAileron Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis - Lelezard
University of Texas Texas AM Investment Management Co. Invests $4.93 Million in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat
Nantahala Capital Management LLC Raises Holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 13.4% in September - MarketBeat
Alumis (NASDAQ:ALMS) Trading 4.8% Higher - MarketBeat
Keeping an Eye on Alx Oncology Holdings Inc (ALXO) After Insider Trading Activity - Knox Daily
Ready to Jump After Recent Trade: Alx Oncology Holdings Inc (ALXO) - SETE News
ALXO stock touches 52-week low at $1.87 amid market challenges - Investing.com
Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - MarketBeat
Market Highlights: Alector Inc (ALEC) Ends on a Low Note at 5.45 - The Dwinnex
What is the investor’s view on Alx Oncology Holdings Inc (ALXO)? - US Post News
Insider Sale Alert: Aldeyra Therapeutics Inc [ALDX] – Is it Time to sell? - Knox Daily
Alector (NASDAQ:ALEC) Shares Down 5.6% - MarketBeat
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - Nasdaq
Market Update: Alx Oncology Holdings Inc (ALXO) Sees Negative Movement, Closing at 2.07 - The Dwinnex
Keith Johns Joins Allurion's Board Of Directors - MPO-mag
HighVista Strategies LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Taking on analysts’ expectations and winning: Alumis Inc. (ALMS) - SETE News
Healius sells Lumus imaging unit to Affinity for USD 657M - Medical Buyer
Australia Medical Diagnostics Firm Healius Sells Lumus to Affinity for $657 Million - BNN Bloomberg
Renaissance Technologies LLC Sells 800 Shares of Alexander’s, Inc. (NYSE:ALX) - Defense World
Alector (NASDAQ:ALEC) Stock Price Up 9% - Defense World
1,959,896 Shares in Alumis Inc. (NASDAQ:ALMS) Bought by SR One Capital Management LP - MarketBeat
Aileron Therapeutics Inc Inc. (ALRN) Price Performance: The Role of Supply and Demand - The InvestChronicle
Closing Bell Recap: Aileron Therapeutics Inc (ALRN) Ends at 2.91, Reflecting a 9.81 Upturn - The Dwinnex
Altair Engineering: Rating Downgrade As Near-Term Upside Is Limited (NASDAQ:ALTR) - Seeking Alpha
Alumis (NASDAQ:ALMS) Shares Down 2.6% - MarketBeat
Alesi Surgical wins FDA clearance for smoke management device and lands new funding - Mass Device
Alector, Inc. (NASDAQ:ALEC) Short Interest Down 5.7% in August - Defense World
Allurion Technologies Inc. (NYSE:ALUR) Short Interest Up 8.6% in August - Defense World
Australia's ALS tumbles on subdued half-year forecast - XM
Market cap of Allarity Therapeutics Inc [ALLR] reaches 4.22M – now what? - The DBT News
Alumis (NASDAQ:ALMS) Stock Price Up 5.3% - Defense World
Alexander's (NYSE:ALX) Hits New 52-Week High at $248.10 - MarketBeat
In the Green: Alector Inc (ALEC) Closes at 5.64, Up/Down -0.70 from Previous Day - The Dwinnex
Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter
Is Alector Inc (ALEC) worth investing in despite its undervalued state? - US Post News
Alector (NASDAQ:ALEC) Receives Overweight Rating from Cantor Fitzgerald - Defense World
Alimera Sciences completes merger with ANI Pharmaceuticals - Investing.com India
Altius Minerals (TSE:ALS) Price Target Raised to C$29.00 at Canaccord Genuity Group - Defense World
Guggenheim raises PT on ANI Pharma after Alimera deal completion - XM
Alumis (NASDAQ:ALMS) Reaches New 12-Month Low at $10.37 - MarketBeat
Prepare Yourself for Liftoff: Alector Inc (ALEC) - SETE News
ANI Pharmaceuticals completes acquisition of Alimera Sciences - TipRanks
ANI Pharmaceuticals completes purchase of Alimera Sciences (NASDAQ:ALIM) - Seeking Alpha
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences - GlobeNewswire
ANI Pharmaceuticals initiates closing of acquisition of Alimera Sciences - TipRanks
Aileron Therapeutics Inc Stock (ALRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aileron Therapeutics Inc Stock (ALRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 14 '24 |
Sale |
3.30 |
1,900 |
6,270 |
1,751,256 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 10 '24 |
Sale |
3.30 |
9,577 |
31,604 |
1,768,250 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 12 '24 |
Sale |
3.25 |
9,342 |
30,362 |
1,753,156 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 11 '24 |
Sale |
3.26 |
5,752 |
18,744 |
1,762,498 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 05 '24 |
Sale |
3.30 |
6,291 |
20,760 |
1,783,851 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 06 '24 |
Sale |
3.29 |
4,284 |
14,104 |
1,779,567 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 07 '24 |
Sale |
3.26 |
1,740 |
5,664 |
1,777,827 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
May 01 '24 |
Sale |
4.21 |
20,315 |
85,473 |
1,779,306 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Apr 29 '24 |
Sale |
4.95 |
10,746 |
53,182 |
1,799,711 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Apr 30 '24 |
Sale |
4.97 |
90 |
448 |
1,799,621 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):